Drugs / vitamin E TPGS
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05429229 | Nov 2021 → Dec 2023 | diabetic retinopathy, disorder of defective peroxisome oxidative status, dry eye syndrome | Adolfo Daniel Rodriguez-Carrizalez | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vitamin E TPGS | “It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol...” NCT05429229 ↗ |
| Known as | D-alpha-tocopheryl polyethylene glycol succinate | “It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol...” NCT05429229 ↗ |
| Route | Topical | “preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS” NCT05429229 ↗ |